Alchemia (ACL) Stock Recommendation

Submitted by Craig Strzelecki on Sat, 05/08/2006 - 15:01.

ABN Amro has rated the Alchemia (ACL) stock with a Buy and a valuation of $3.55 per share. The broker has noted that the company has also entered a collaboration with another European drug company to search for new drug candidates, providing future upside potential if any successful developments are made.

Alchemia Limited is listed on the Australian Stock Exchange (ASX) under stock code ACL. You can view their investor website here. The company is involved in the development of carbohydrate-based molecules for therapeutic applications. The company is in the Pharmaceuticals, Biotechnology & Life Sciences Industry Group. Check your charts!

Free Email Subscription to Share Trading

 My Share Trading Feed